血管生成抑制剂联合化疗治疗复发性卵巢癌疗效与安全性Meta分析

发布时间：2018-03-06 10:53

  本文选题：血管生成抑制剂　切入点：复发性卵巢癌　出处：《中国实用妇科与产科杂志》2017年03期 　论文类型：期刊论文

【摘要】：目的探讨血管生成抑制剂联合化疗治疗复发性卵巢癌的疗效与安全性。方法检索Pub Med、Embase、Cochrane Library、中国生物医学文献数据库、中国知网、维普与万方数据库,收集和评价国内外从建库至2016年1月血管生成抑制剂联合化疗与常规化疗相比较治疗复发性卵巢癌的疗效与安全性的随机对照试验(RCT)。由2名研究者独立筛选提取文献资料、评价偏倚风险后,采用Rev Man5.3软件进行Meta分析。结果共纳入6个RCT,2028例复发性卵巢癌患者。结果显示:(1)血管生成抑制剂联合化疗组较常规化疗组(对照组)可延长总生存期(OS)[HR=0.87,95%CI(0.76,0.99)]和无进展生存期(PFS)[HR=0.56,95%CI(0.47,0.67)],差异均有统计学意义(P0.05)。(2)药物安全性结果显示:≥3级总不良反应发生率血管生成抑制剂联合化疗组与对照组间差异无统计学意义(P0.05),常见不良反应中抗血管内皮生长因子(anti-VEGF)抑制剂联合化疗组≥3级高血压、蛋白尿发生率较高;抗血管内皮生长因子受体(anti-VEGFR)抑制剂联合化疗组≥3级蛋白尿及≤2级腹泻、呕吐等不良反应发生率较高;抗促血管生成素(anti-ANG)抑制剂联合化疗组≤2级外周水肿发生率较高,以上差异均有统计学意义(P0.05)。结论血管生成抑制剂联合化疗可提高复发性卵巢癌患者OS及PFS,总不良反应发生率与常规化疗组相当。不同作用机制的血管生成抑制剂发生不良反应类型及严重程度具有一定差异。
[Abstract]:Objective to investigate the efficacy and safety of angiogenesis inhibitor combined with chemotherapy in the treatment of recurrent ovarian cancer. Methods Pub Medbase Cochrane Library, Chinese Biomedical Literature Database, China knowledge Network, Weip and Wanfang databases were searched. To collect and evaluate the efficacy and safety of angiogenesis inhibitors combined with chemotherapy and conventional chemotherapy in the treatment of recurrent ovarian cancer from the establishment of the bank to January 2016, a randomized controlled trial was conducted to collect and evaluate the efficacy and safety of chemotherapy in the treatment of recurrent ovarian cancer. After evaluating the risk of bias, Meta analysis was carried out with Rev Man5.3 software. Results A total of 2 028 patients with recurrent ovarian cancer were included in this study. The results showed that the total survival time of the angiogenesis inhibitor combined chemotherapy group was significantly longer than that of the conventional chemotherapy group (control group). Survival time (PFS) [HRN 0.5695 CIQ 0.470.67], the difference was statistically significant (P 0.05. 0. 0. 2) the results showed that there was no significant difference between the angiogenesis inhibitor combined with chemotherapy group and the control group in the incidence of total adverse drug reactions (鈮，

本文编号：1574545